Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1618-1624

  Han, Yili ^a   Luo, Yong ^a   Zhao, Jiahui ^a   Li, Mingchuan ^a   Jiang, Yongguang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

c Met; Epithelial mesenchymal transition; Invasive potency; Prostate cancer

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

EID: 84940263337     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2390     Document Type: Article

References (48)

1. Jeffers M, Rong S and Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125, 1996.
2. Ponzetto C, Bardelli A, Zhen Z, et al: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261-271, 1994.
3. Birchmeier C and Gherardi E: Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8: 404-410, 1998.
4. Bhardwaj V, Cascone T, Cortez MA, et al: Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119: 1768-1775, 2013.
5. Gibney GT, Aziz SA, Camp RL, et al: c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24: 343-349, 2013.
6. Knudsen BS and Vande Woude G: Showering c-Met dependent cancers with drugs. Curr Opin Genet Dev 18: 87-96, 2008.
7. De Bacco F, Luraghi P, Medico E, et al: Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 103: 645-661, 2011.
8. Qian LW, Mizumoto K, Inadome N, et al: Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer 104:542-549, 2003.
9. Graveel CR, Tolbert D and Vande Woude GF: MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 5: a009209, 2013.
10. Luraghi P, Schelter F, Krüger A and Boccacciol C: The MET oncogene as a therapeutical target in cancer invasive growth. Front Pharmacol 3: 164, 2012.
11. Feng Y, Thiagarajan PS and Ma PC: MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 7: 459-467, 2012.
12. Li B, Torossian A, Sun Y, Du R, Dicker AP and Lu B: Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys 84: e525-e531, 2012.
13. Seiden-Long I, Navab R, Shih W, et al: Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis 29: 647-655, 2008.
14. Chung JY, Davis JA, Price BD, et al: Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Exp Cell Res 317: 307-318, 2011.
15. Ogunwobi OO and Liu C: Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathway. Clin Exp Metastasis 28: 721-731, 2011.
16. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P and Desiderio MA: Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways. Eur J Cancer 46:1679-1691, 2010.
17. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC and Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298, 1995.
18. Cecchi F, Rabe DC and Bottaro DP: Targeting the HGF/Met signaling pathway in cancer. Eur J Cancer 46: 1260-1270, 2010.
19. Luo Y, He DL and Ning L: Expression of 'epithelial-mesenchymal transition'associated proteins in prostate cancer cell lines with different metastatic potentials and its significance. Zhonghua Nan Ke Xue 12: 696-700, 2006 (In Chinese).
20. McKeithen D, Graham T, Chung LW and Odero-Marah V: Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 70: 982-992, 2010.
21. Wang Y, Yue D, Li K, Liu YL, Ren CS and Wang P: The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl 12: 841-852, 2010.
22. Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW and Edlund M: Met-independent hepatocyte growth factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer 6: 197, 2006.
23. Ksia{ogonek}żkiewicz M, Markiewicz A and Zaczek AJ: Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 79: 195-208, 2012.
24. Voutsadakis IA: The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci 19: 67, 2012.
25. Matsuoka J, Yashiro M, Doi Y, et al: Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGFβsignaling. PLoS One 8: e62310, 2013.
26. Luo Y, He DL, Ning L, et al: Over-expression of hypoxia-inducible factor-1αincreases the invasive potency of LNCaP cells in vitro. BJU Int 98: 1315-1319, 2006.
27. Lamouille S, Subramanyam D, Blelloch R and Derynck R: Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol 25: 200-207, 2013.
28. Davidson B, Tropé B and Reich R: Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol 2: 33, 2012.
29. Hamada S, Satoh K, Masamune A and Shimosegawa T: Regulators of epithelial mesenchymal transition in pancreatic cancer. Front Physiol 3: 254, 2012.
30. Talbot LJ, Bhattacharya SD and Kuo PC: Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol 3: 117-136, 2012.
31. Leopold PL, Vincent J and Wang H: A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol 22: 471-483, 2012.
32. Navab R, Liu J, Seiden-Long I, et al: Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11: 1292-1300, 2009.
33. Garnett J, Chumbalkar V, Vaillant B, et al: Regulation of HGF expression by {increment}EGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 15: 73-84, 2013.
34. Varkaris A, Gaur S, Parikh NU, et al: Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer 133: 1536-1546, 2013.
35. Nurwidya F, Takahashi F, Murakami A and Takahashi K: Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 44: 151-156, 2012.
36. Shimada S, Mimata A, Sekine M, et al: Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 61: 344-353, 2012.
37. Jahn SC, Law ME, Corsino PE, et al: An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett 326: 183-190, 2012.
38. Martin TA, Mason MD and Jiang WG: Hepatocyte growth factor signaling in cancer metastasis. Curr Signal Transduct Ther 6: 180-190, 2011.
39. Thiery JP, Acloque H, Huang RY and Nieto A: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
40. Gentile A, Trusolino L and Comoglio PM: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27: 85-94, 2008.
41. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003.
42. Benvenuti S and Comoglio PM: The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213: 316-325, 2007.
43. Torres KE, Zhu QS, Bill K, et al: Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 17: 3943-3955, 2011.
44. Lengyel E, Prechtel D, Resau JH, et al: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113: 678-682, 2005.
45. Zhou AX, Toylu A, Nallapalli RK, et al: Filamin a mediates HGF/c-MET signaling in tumor cell migration. Int J Cancer 128: 839-846, 2011.
46. Inagaki Y, Qi F, Gao J, et al: Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends 5: 52-56, 2011.
47. Falchook GS, Fu S, Amin HM, et al: Phase I dose-escalation study of the oral selective C-Met inhibitor EMD 1204831 in patients with advanced solid tumours. Eur J Cancer 47: S158, 2011.
48. Yap TA, Olmos D, Brunetto AT, et al: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29: 1271-1279, 2011.